Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com

StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT) from a sell rating to a hold rating in a report published on Tuesday.

Separately, HC Wainwright restated a buy rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, April 9th.

Galectin Therapeutics Price Performance

GALT stock opened at $3.05 on Tuesday. Galectin Therapeutics has a 52-week low of $1.28 and a 52-week high of $4.27. The company’s 50 day simple moving average is $3.10 and its 200-day simple moving average is $2.27. The firm has a market capitalization of $189.56 million, a P/E ratio of -4.12 and a beta of 0.72.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Sell-side analysts predict that Galectin Therapeutics will post -0.66 EPS for the current fiscal year.

Insider Buying and Selling at Galectin Therapeutics

In other Galectin Therapeutics news, major shareholder James C. Czirr sold 21,323 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $3.06, for a total value of $65,248.38. Following the transaction, the insider now owns 5,925,884 shares in the company, valued at approximately $18,133,205.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last quarter, insiders have purchased 4,500 shares of company stock worth $14,360. 52.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GALT. Wealthspire Advisors LLC increased its stake in Galectin Therapeutics by 116.7% in the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock valued at $952,000 after buying an additional 214,512 shares during the period. Vanguard Group Inc. grew its position in Galectin Therapeutics by 2.0% in the first quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after acquiring an additional 38,037 shares in the last quarter. Solutions 4 Wealth Ltd bought a new stake in Galectin Therapeutics in the fourth quarter worth approximately $60,000. Retirement Guys Formula LLC grew its position in Galectin Therapeutics by 56.9% in the first quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock worth $81,000 after acquiring an additional 12,232 shares in the last quarter. Finally, Beacon Capital Management LLC grew its position in Galectin Therapeutics by 89.6% in the fourth quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock worth $40,000 after acquiring an additional 11,300 shares in the last quarter. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.